This week, we dissect Appen’s latest acquisition and touch on the ethics of AI.
We look to why shares in Envirosuite have surged higher, and ask whether the phenomenal gains from Clinuval Pharmaceuticals and Advance NanoTek can continue.
Plus Matt updates us on his recent meeting with the PushPay team.
Email us at [email protected]
Return to the Strawman Platform here
Strawman is Australia’s premier online investment club. Join for free to access independent & actionable recommendations from proven private investors.
© 2019 Strawman Pty Ltd. All rights reserved.
ACN: 610 908 211 | Australian Financial Services Licence (AFSL): 501223